Nanovibronix, Inc. (NASDAQ:FEED) Stock Short Interest Falls 81.6%

Nanovibronix, Inc. (NASDAQ:FEED) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 16,107 shares, a decrease of 81.6% from the August 31st total of 87,719 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 196,700 shares, the days-to-cover ratio is currently 0.1 days.

Nanovibronix Stock Down 17.3%

NASDAQ:FEED traded down $0.09 on Friday, hitting $0.41. The stock had a trading volume of 10,594 shares, compared to its average volume of 406,886. The company has a fifty day moving average price of $3.73 and a two-hundred day moving average price of $10.55. Nanovibronix has a 1-year low of $0.36 and a 1-year high of $89.40. The stock has a market cap of $374,220.00, a price-to-earnings ratio of -0.00 and a beta of 1.38.

Nanovibronix (NASDAQ:FEED) last released its quarterly earnings results on Monday, August 17th. The company reported ($23.76) EPS for the quarter. The firm had revenue of $0.24 million for the quarter. Nanovibronix had a negative return on equity of 60.73% and a negative net margin of 1,093.61%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a research report on Tuesday, July 21st. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

About Nanovibronix

NanoVibronix, Inc is a medical device company focused on developing and commercializing noninvasive therapeutic devices that use low-intensity surface acoustic wave technology. Its products are designed to support pain management, wound care and other clinical applications.

The company’s product portfolio has included PainShield, a wearable therapeutic ultrasound device intended to provide localized pain relief, and WoundShield, a device designed to support wound-care treatment. NanoVibronix has also developed UroShield, which is intended for the management of urinary discomfort and related conditions.

NanoVibronix has served healthcare providers and patients in the United States and international markets through medical distribution and sales channels.